Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

The chronic and progressive inflammatory disease bronchiectasis is characterised by permanent bronchi dilation and by ...

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

The global nasal sprays market is on an exceptional growth trajectory, projected to reach an impressive USD 32.6 billion by 2033, according to a recent study by Future Market Insights. A robust ...

Boehringer Ingelheim has announced an increase in ... said the company hopes to offset the falling sales by getting new respiratory drugs approved, and the company hopes that Spiolto, more ...

The global Cattle & Porcine/Swine Reproductive Diseases market is expected to grow to USD 975.8 Million by 2029, up from USD ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some types of respiratory ... German partner Boehringer Ingelheim have won ...

The global ruminant vaccines market, valued at USD 3.51 billion in 2023, is projected to grow significantly at a compound annual growth rate (CAGR) of 6.95% from 2024 to 2032. Read the Market Summary ...